Related references
Note: Only part of the references are listed.A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer
Robin M. Hallett et al.
SCIENTIFIC REPORTS (2012)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Multifactorial Approach to Predicting Resistance to Anthracyclines
Christine Desmedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor Topoisomerase II Alpha Status and Response to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
Aliz Nikolenyi et al.
ONCOLOGY (2011)
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
David Venet et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer
Jae K. Lee et al.
CLINICAL CANCER RESEARCH (2010)
Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu-Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea
Chau Dang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An algorithm to discover gene signatures with predictive potential
Robin M. Hallett et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program
John F. Scoggins et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
Nicolai Juul et al.
LANCET ONCOLOGY (2010)
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
Christina Yau et al.
BREAST CANCER RESEARCH (2010)
Overexpression of Class III β-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma
Daisuke Aoki et al.
CLINICAL CANCER RESEARCH (2009)
Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers
Dennis J. Slamon et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists
Jonathan D. Mosley et al.
BMC MEDICAL GENOMICS (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
Chromatin remodeling and SWI/SNF2 factors in human disease
Juraj Kokavec et al.
FRONTIERS IN BIOSCIENCE (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Darren J. Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
Pratyaksha Wirapati et al.
BREAST CANCER RESEARCH (2008)
Cytoskeleton and paclitaxel sensitivity in breast cancer:: The role of β-tubulins
Stefania Tommasi et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
Vincent Vuaroqueaux et al.
BREAST CANCER RESEARCH (2007)
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
Kenneth R. Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients
HY Dai et al.
CANCER RESEARCH (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Chromatin remodeling and human disease
C Huang et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2003)
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
RA Irizarry et al.
BIOSTATISTICS (2003)
Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
M. Abal et al.
CURRENT CANCER DRUG TARGETS (2003)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Exo1 roles for repair of DNA double-strand breaks and meiotic crossing over in Saccharomyces cerevisiae
H Tsubouchi et al.
MOLECULAR BIOLOGY OF THE CELL (2000)
TPX2, a novel Xenopus MAP involved in spindle pole organization
T Wittmann et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
